JP2021525248A5 - - Google Patents
Info
- Publication number
- JP2021525248A5 JP2021525248A5 JP2020565359A JP2020565359A JP2021525248A5 JP 2021525248 A5 JP2021525248 A5 JP 2021525248A5 JP 2020565359 A JP2020565359 A JP 2020565359A JP 2020565359 A JP2020565359 A JP 2020565359A JP 2021525248 A5 JP2021525248 A5 JP 2021525248A5
- Authority
- JP
- Japan
- Prior art keywords
- region
- compound
- sequence number
- seq
- cdr1l
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023093659A JP7550922B2 (ja) | 2018-05-23 | 2023-06-07 | 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862675639P | 2018-05-23 | 2018-05-23 | |
| US62/675,639 | 2018-05-23 | ||
| PCT/US2019/033505 WO2019226761A1 (en) | 2018-05-23 | 2019-05-22 | Antiproliferative compounds and bispecific antibody against bcma and cd3 for combined use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023093659A Division JP7550922B2 (ja) | 2018-05-23 | 2023-06-07 | 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021525248A JP2021525248A (ja) | 2021-09-24 |
| JP2021525248A5 true JP2021525248A5 (enExample) | 2022-05-30 |
| JP7293256B2 JP7293256B2 (ja) | 2023-06-19 |
Family
ID=66999900
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565359A Active JP7293256B2 (ja) | 2018-05-23 | 2019-05-22 | 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体 |
| JP2023093659A Active JP7550922B2 (ja) | 2018-05-23 | 2023-06-07 | 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023093659A Active JP7550922B2 (ja) | 2018-05-23 | 2023-06-07 | 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11439637B2 (enExample) |
| EP (2) | EP3796912B1 (enExample) |
| JP (2) | JP7293256B2 (enExample) |
| KR (1) | KR102813281B1 (enExample) |
| CN (2) | CN113713095B (enExample) |
| AU (1) | AU2019274530B2 (enExample) |
| BR (1) | BR112020023704A2 (enExample) |
| CA (1) | CA3101050A1 (enExample) |
| CY (1) | CY1126060T1 (enExample) |
| DK (1) | DK3796912T5 (enExample) |
| EA (1) | EA202092830A1 (enExample) |
| ES (1) | ES2945214T3 (enExample) |
| FI (1) | FI3796912T3 (enExample) |
| HR (1) | HRP20230449T1 (enExample) |
| HU (1) | HUE061792T2 (enExample) |
| IL (1) | IL278853B2 (enExample) |
| LT (1) | LT3796912T (enExample) |
| MX (1) | MX420366B (enExample) |
| PL (1) | PL3796912T3 (enExample) |
| PT (1) | PT3796912T (enExample) |
| RS (1) | RS64189B1 (enExample) |
| SG (1) | SG11202011545YA (enExample) |
| SI (1) | SI3796912T1 (enExample) |
| SM (1) | SMT202300142T1 (enExample) |
| WO (1) | WO2019226761A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7258009B2 (ja) * | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | 抗増殖化合物及びその使用方法 |
| IL278854B2 (en) | 2018-05-23 | 2026-01-01 | Celgene Corp | Multiple myeloma treatment and biomarker use for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl-3-fluorobenzonitrile |
| CN113573719A (zh) | 2018-11-08 | 2021-10-29 | 朱诺治疗学股份有限公司 | 治疗和t细胞调节的方法和组合 |
| JP2020103414A (ja) * | 2018-12-26 | 2020-07-09 | 株式会社三洋物産 | 遊技機 |
| DK3908281T3 (da) * | 2019-01-09 | 2024-10-21 | Celgene Corp | Antiproliferative forbindelser og sekundære aktive midler til anvendelse til behandling af multipelt myelom |
| EP3908582B1 (en) * | 2019-01-09 | 2025-11-12 | Celgene Corporation | Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same |
| AU2020206692B2 (en) | 2019-01-09 | 2025-03-27 | Celgene Corporation | Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same |
| HUE068401T2 (hu) | 2019-11-11 | 2024-12-28 | Amgen Res Munich Gmbh | A BCMA elleni hatóanyagok adagolási rendje |
| EP4095132A1 (en) * | 2020-01-20 | 2022-11-30 | Kangpu Biopharmaceuticals, Ltd. | Isoindoline derivative, and pharmaceutical composition and use thereof |
| JP2021133199A (ja) * | 2020-02-28 | 2021-09-13 | 株式会社三洋物産 | 遊技機 |
| JP2021133198A (ja) * | 2020-02-28 | 2021-09-13 | 株式会社三洋物産 | 遊技機 |
| JP2021133200A (ja) * | 2020-02-28 | 2021-09-13 | 株式会社三洋物産 | 遊技機 |
| CA3181399A1 (en) * | 2020-04-28 | 2021-11-04 | Juno Therapeutics, Inc. | Combination of bcma-directed t cell therapy and an immunomodulatory compound |
| AU2021263408A1 (en) | 2020-04-30 | 2022-10-27 | Bristol-Myers Squibb Company | Methods of treating cytokine-related adverse events |
| JP2021186294A (ja) * | 2020-05-29 | 2021-12-13 | 株式会社三洋物産 | 遊技機 |
| JP2022012088A (ja) * | 2020-06-30 | 2022-01-17 | 株式会社三洋物産 | 遊技機 |
| JP2022012089A (ja) * | 2020-06-30 | 2022-01-17 | 株式会社三洋物産 | 遊技機 |
| JP2022012090A (ja) * | 2020-06-30 | 2022-01-17 | 株式会社三洋物産 | 遊技機 |
| ES2988714T3 (es) | 2020-07-07 | 2024-11-21 | Celgene Corp | Composiciones farmacéuticas que comprenden (S)-4-(4-(4-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)bencilo)piperazin-1-il)-3-fluorobenzonitrilo y métodos de uso de las mismas |
| CA3202891A1 (en) | 2021-01-28 | 2022-08-04 | Kara Olson | Compositions and methods for treating cytokine release syndrome |
| AU2023254191A1 (en) | 2022-04-11 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| AU2024223918A1 (en) | 2023-02-17 | 2025-09-11 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
| US20260158137A1 (en) * | 2024-09-10 | 2026-06-11 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with lag3 inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| EP1456652A4 (en) | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| TWI409079B (zh) | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法 |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| HUE057285T2 (hu) | 2015-04-13 | 2022-04-28 | Pfizer | Terápiás ellenanyagok és alkalmazásaik |
| CA2992797A1 (en) * | 2015-08-03 | 2017-02-09 | Engmab Sarl | Monoclonal antibodies against bcma |
| US10238225B2 (en) * | 2016-06-08 | 2019-03-26 | Windor Enterprises, LLC | Compression garment donning aid device, method, and kit |
| CN109983027A (zh) | 2016-10-20 | 2019-07-05 | 细胞基因公司 | 基于cereblon的可异二聚化嵌合抗原受体 |
| US11124577B2 (en) * | 2016-11-02 | 2021-09-21 | Engmab Sàrl | Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma |
| JP7258009B2 (ja) * | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | 抗増殖化合物及びその使用方法 |
-
2019
- 2019-05-22 PL PL19732494.0T patent/PL3796912T3/pl unknown
- 2019-05-22 SM SM20230142T patent/SMT202300142T1/it unknown
- 2019-05-22 PT PT197324940T patent/PT3796912T/pt unknown
- 2019-05-22 US US16/419,971 patent/US11439637B2/en active Active
- 2019-05-22 SI SI201930535T patent/SI3796912T1/sl unknown
- 2019-05-22 CN CN202110586843.4A patent/CN113713095B/zh active Active
- 2019-05-22 RS RS20230351A patent/RS64189B1/sr unknown
- 2019-05-22 HU HUE19732494A patent/HUE061792T2/hu unknown
- 2019-05-22 HR HRP20230449TT patent/HRP20230449T1/hr unknown
- 2019-05-22 WO PCT/US2019/033505 patent/WO2019226761A1/en not_active Ceased
- 2019-05-22 EP EP19732494.0A patent/EP3796912B1/en active Active
- 2019-05-22 SG SG11202011545YA patent/SG11202011545YA/en unknown
- 2019-05-22 ES ES19732494T patent/ES2945214T3/es active Active
- 2019-05-22 CA CA3101050A patent/CA3101050A1/en active Pending
- 2019-05-22 EP EP23156579.7A patent/EP4218762A3/en active Pending
- 2019-05-22 BR BR112020023704-3A patent/BR112020023704A2/pt unknown
- 2019-05-22 DK DK19732494.0T patent/DK3796912T5/da active
- 2019-05-22 KR KR1020207036733A patent/KR102813281B1/ko active Active
- 2019-05-22 AU AU2019274530A patent/AU2019274530B2/en active Active
- 2019-05-22 CN CN201980046500.XA patent/CN112399848B/zh active Active
- 2019-05-22 EA EA202092830A patent/EA202092830A1/ru unknown
- 2019-05-22 LT LTEPPCT/US2019/033505T patent/LT3796912T/lt unknown
- 2019-05-22 FI FIEP19732494.0T patent/FI3796912T3/fi active
- 2019-05-22 IL IL278853A patent/IL278853B2/en unknown
- 2019-05-22 JP JP2020565359A patent/JP7293256B2/ja active Active
- 2019-05-22 MX MX2020012485A patent/MX420366B/es unknown
-
2022
- 2022-08-17 US US17/820,534 patent/US12053466B2/en active Active
-
2023
- 2023-05-15 CY CY20231100227T patent/CY1126060T1/el unknown
- 2023-06-07 JP JP2023093659A patent/JP7550922B2/ja active Active
-
2024
- 2024-06-25 US US18/753,467 patent/US20240366593A1/en active Pending